Nightingale Health is The Preventative Health Company.
Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. We have customers in more than 25 countries in the healthcare and medical research sectors. Our technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology.
The company was founded based on scientific innovation: a blood test that can detect a wide variety of molecules from a single sample.
Read more about our proprietary technology.
Our blood analysis technology was, and still is, widely used by world-leading scientists making novel findings in the field of chronic diseases.
Browse the list of publications.
We obtained our first regulatory approvals, paving the way for healthcare use. Our quality management system was certified and we received a CE marking for the blood analysis technology.
We kicked off a multi-year collaboration with the world’s largest biobank: UK Biobank.
Additionally, we won multiple awards including Health Innovation of the Year, Finnish Startup of the Year, and Best Health Tech Startup of the Year.
Read more about our collaboration with UK Biobank.
We expanded to the United States by setting up a laboratory in Pittsburgh, Pennsylvania in collaboration with our shareholder PerkinElmer Inc.
Additionally, we became a private healthcare service provider and launched a pilot of our first direct-to-consumer service in Finland.
We expanded to Japan in collaboration with our shareholder Mitsui & Co, Ltd. As part of the expansion, we set up an office and laboratory in the heart of Tokyo.
Our Series B shares were listed on the Nasdaq Helsinki First North Growth Market, and we raised EUR 110 million in new funding to grow the company.
Visit our investor pages.
We launched the direct-to-consumer service Livit by Nightingale Health which utilizes at-home blood collection.
Additionally, we announced our expansion into genetics and launched an international center of excellence for genomic data analysis.
Read our latest news.
Chief Executive Officer, Founder
Chief Technology Officer, Founder
Chief Operating Officer
Chief Legal Officer
Chief Financial Officer
Salla Ruosaari, PhD
Chief R&D Officer
Jeffrey Barrett, PhD, FMedSci
Chief Scientific Officer
Pasi Soininen, PhD
Laboratory Director, Founder
Peter Würtz, PhD
Scientific Director, Founder
- Antti Kangas
- Olli Karhi, MD
- Ilkka Laurila
- Leena Niemistö, MD, PhD
- Timo Soininen
- Teemu Suna
- Prof. John Danesh
- Prof. José Ordovás
- Prof. Eline Slagboom
- Prof. George Davey Smith
Nightingale Health Plc
HQ & Laboratory
Mannerheimintie 164a, 00300 Helsinki, Finland
Neulaniementie 2, 70210 Kuopio, Finland
Nightingale Health Estonia OÜ
Rotermanni tn 14, 10111
Nightingale Health Germany GmbH
Nightingale Health Japan KK
Office & Laboratory
Uchikanda Mid Square 1F
Uchikanda 1-16-8, Chiyoda-ku
Nightingale Health Asia Pte. Ltd.
10 Anson Road, #22-06,
NG Health Sweden AB
111 22 Stockholm
Nightingale Health UK Limited
5 New Street Square
EC4A 3TW London
Nightingale Health United States, Inc.
6325 Main Street, Suite 100,
Williamsville, NY 14221